Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection

COVID-19 pandemic represented a challenge in the management of treatments for Multiple Sclerosis (MS), such as Natalizumab (NTZ). NTZ interferes with the homing of lymphocytes into the central nervous system, reducing immune surveillance against opportunistic infection. Although NTZ efficacy starts...

Descripción completa

Detalles Bibliográficos
Autores principales: Landi, Doriana, Cola, Gaia, Mantero, Vittorio, Balgera, Roberto, Moiola, Lucia, Nozzolillo, Agostino, Dattola, Vincenzo, Sinisi, Leonardo, Fantozzi, Roberta, Di Lemme, Sonia, Centonze, Diego, Mataluni, Giorgia, Nicoletti, Carolina Gabri, Marfia, Girolama Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542399/
https://www.ncbi.nlm.nih.gov/pubmed/35158454
http://dx.doi.org/10.1016/j.msard.2021.103345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542399/
https://www.ncbi.nlm.nih.gov/pubmed/35158454
http://dx.doi.org/10.1016/j.msard.2021.103345

Ejemplares similares